Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Enterprise Value: 2010-2025

Historic Enterprise Value for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $137.7 million.

  • Heron Therapeutics' Enterprise Value fell 40.39% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year decrease of 211.03%. This contributed to the annual value of $173.4 million for FY2024, which is 0.74% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Enterprise Value is $137.7 million, which was down 49.97% from $275.2 million recorded in Q2 2025.
  • Heron Therapeutics' Enterprise Value's 5-year high stood at $1.3 billion during Q2 2021, with a 5-year trough of $67.6 million in Q3 2023.
  • Its 3-year average for Enterprise Value is $215.9 million, with a median of $174.7 million in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Enterprise Value plummeted by 84.70% in 2022 and then surged by 335.45% in 2024.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Enterprise Value stood at $773.1 million in 2021, then tumbled by 72.53% to $212.4 million in 2022, then declined by 17.73% to $174.7 million in 2023, then fell by 0.74% to $173.4 million in 2024, then slumped by 40.39% to $137.7 million in 2025.
  • Its Enterprise Value was $137.7 million in Q3 2025, compared to $275.2 million in Q2 2025 and $284.4 million in Q1 2025.